Blood Testing and Typing Market Exceeds $2 Billion: Report

ROCKVILLE, Md., June 14, 2017 /PRNewswire/ -- The total global market for blood testing and typing products  used in blood banking/donations of pooled blood reached $2.6 billion dollars in 2016, according to Kalorama Information.  The publisher is a leading provider of information for testing markets and covers all types of clinical testing.  The firm said that blood banking is not a fast-growing market, and tends to grow only when new diseases are added to testing menu.  Kalorama Information's most recent report, Blood Testing and Typing Post-Zika, examines testing markets in the wake of an increased vigilance by U.S. health authorities and cases of Zika and other diseases.

"Although no dramatic change in the testing industry is expected, new guidelines and disease concerns make it a worthwhile time for business planners to revisit test market assumptions," said Bruce Carlson, Publisher of Kalorama Information. 

In its market calculation, Kalorama includes the three common types of tests related to blood banking:

• Immunoassays for HIV, hepatitis B, hepatitis C and syphilis have been the routine approach to testing blood units for blood borne infectious agents. All blood banks in Latin America also screen donated units for Chagas disease. Blood banks in some developing countries additionally screen for Dengue fever and malaria, diseases which are both common and deadly in many tropical nations.
  
  
• Blood grouping and typing reagents and instruments are used by blood transfusion services, hospital and private blood banks and hospital laboratories that prepare blood units for transfusion to patients. Blood bank lab systems blood tracking because of the serious error of giving a patient the wrong blood.
  
  
• Nucleic acid testing (NAT) has allowed blood banks to detect viral contamination, including West Nile Virus, HIV and hepatitis C, sooner and prevent them from slipping into blood transfusions. These benefits have enabled it to become an integral part of the concerted effort to make blood transfusions safer. Once a test is introduced to the blood bank/plasmapheresis arena, it is rapidly accepted - by necessity. It is estimated that approximately 53 million units of blood are screened with NAT. Commonly used NAT assays detect HIV-1 RNA, HCV RNA, HBV DNA, and West Nile Virus (WNV) RNA Virtually all of the blood drawn in North America, Europe and Japan is now tested for West Nile virus, HIV and HCV by NAT.

Companies such as Roche Diagnostics, Bio-Rad, Grifols, Ortho Clinical Diagnostics and Abbott compete in this market place. 

Kalorama Information's report contains additional charts depicting market share, segmentation, market forecasts and other data.  The report can be found at:  https://www.kaloramainformation.com/Blood-Testing-Typing-Post-Zika-10915037/.

About Kalorama Information

Kalorama Information, a division of MarketResearch.com, supplies the latest in independent medical market research in diagnostics, biotech, pharmaceuticals, medical devices and healthcare; as well as a full range of custom research services. Reports can be purchased through Kalorama's website and are also available on www.marketresearch.com and www.profound.com.

We routinely assist the media with healthcare topics. Follow us on Twitter, LinkedIn and our blog on our company website.  

Please link any media or news references to our reports or data to http://www.kaloramainformation.com/.

Press Contact: 
Bruce Carlson
212 807 2262
[email protected]

SOURCE Kalorama Information

Related Links

http://www.kaloramainformation.com